Johnson & Johnson to Acquire Intra-Cellular

Johnson & Johnson has decided to obtain Intra-Cellular Therapies, signaling a strategic expansion into the field of central nervous system treatments. This acquisition is agreed upon at an approximated value of $14.6 billion.

Focus on Neurological Treatments

Intra-Cellular Therapies is renowned for its specialization in therapies aimed at disorders involving the central nervous system. This acquisition suggests that Johnson & Johnson seeks to strengthen its portfolio in this important and growing area of healthcare.

Details and Reporting

The announcement of this significant acquisition was detailed by Katie Greifeld during Bloomberg’s ‘Open Interest’ segment. The report provided insights into the expected impacts and strategic benefits of the deal for both companies involved.